Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced financial results for the third quarter of 2016 and provided a business update. “In the third quarter, we …
J.P.
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi announced the U.S.
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Teva Pharmaceutical (NYSE:TEVA) provided an update on fasinumab, triggered by a recent development in a Phase 2b fasinumab study …
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced topline results from the Phase 2 CAPELLA study evaluating aflibercept co-formulated with rinucumab, an anti-platelet-derived growth factor receptor …
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi SA (ADR) (NYSE:SNY) announced that the U.S.
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Teva Pharmaceutical Industries Ltd (ADR)(NYSE:TEVA) announced a globa agreement to develop and commercialize fasinumab, Regeneron’s investigational NGF antibody in …
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi announced detailed positive results from ODYSSEY ESCAPE, a Phase 3 trial which evaluated Praluent® (alirocumab) Injection in …
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced an agreement with theBiomedical Advanced Research and Development Authority (BARDA) of the U.S.
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) released its second-quarter earnings results today, with U.S.